Sign up Australia
Proactive Investors - Run By Investors For Investors

Actinogen extends Alzheimer's drug patent protection in Europe

 Actinogen extends Alzheimer's drug patent protection in Europe

Actinogen (ASX:ACW) has received official notification to grant from the European Union Patent Office for patent application 11709770.9.

This protects the use ACW's Xanamem™ for use in Alzheimer’s dementia and other related diseases associated with the inhibition of 11-beta-hydroxysteroid dehydrogenase.

Importantly this European patent further extends the comprehensive cover to 2031.

The claims in these patents cover method-to-treat for various diseases beyond Alzheimer’s dementia such as type 2 diabetes and obesity, hypertension, and cardiovascular disorders.

They also cover central nervous system disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease, post-traumatic stress disorder, depression, and schizophrenia.

Xanamem™ inhibits an enzyme that reduces cortisone to the active hormone cortisol, which activates glucocorticoid receptors.

The cost of Alzheimer’s treatment in the US alone was estimated to be US$250 billion last year by the American Alzheimer’s Association.

The drug works by blocking the development of cortisol - the stress hormone - in the hippocampus, the area of the brain most affected by Alzheimer’s disease.

There is growing evidence that chronic stress and elevated cortisol levels lead to changes in the brain affecting memory and to the development of amyloid plaques and neural death, which are the hallmarks of Alzheimer’s disease.

Actinogen is currently completing a second Phase I study on Xanamem™ with results expected mid-2015.

It is set to start a Phase II Alzheimer’s dementia study in early 2016 which is planned to run in Australia, New Zealand, Europe and the USA, under a US Food & Drug Administration approved Investigational New Drug.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full ACW profile View Profile

Actinogen Medical Ltd Timeline

Newswire
December 30 2016

Related Articles

test tubes
January 23 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions
e-Therapeutics
August 17 2017
E-Therapeutics’ network-driven drug discovery platform looks at the broader interactions within disease mechanisms
t-cell
Wed
£1,000 invested at float two years ago would now be worth just north of £3,500

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use